Nigrostriatal Dopamine Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The nigrostriatal pathway is a critical dopaminergic neural tract that originates in the substantia nigra pars compacta (SNc) and projects to the striatum (comprising the caudate nucleus and putamen). This pathway constitutes the major neurotransmitter system governing voluntary motor control and movement execution. The nigrostriatal system is named for its anatomical trajectory: "nigro-" refers to the substantia nigra (Latin for "black substance"), while "-striatal" denotes its termination in the striatum.
In Parkinson's disease (PD), the nigrostriatal dopamine neurons undergo progressive degeneration, leading to the characteristic motor symptoms including resting tremor, bradykinesia, rigidity, and postural instability. The loss of these neurons is one of the hallmark neuropathological features of PD, with approximately 70-80% of SNc dopamine neurons lost by the time of clinical diagnosis.
The nigrostriatal dopamine neurons are the primary casualties in Parkinson's disease:
The study of Nigrostriatal Dopamine Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Bezard E, Gross CE, Brotchie JM. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 2003;26(4):215-221. PMID:12689772
Surmeier DJ, Ding J, Day J, Wang Z, Shen W. D1 and D2 dopamine-receptor-mediated modulation of striatal glutamatergic signaling in normal and Parkinsonian rats. J Neurochem. 2007;101(2):311-320. PMID:17254014
Kalia LV, Lang AG. Parkinson's disease. Lancet. 2015;386(9996):896-912. PMID:25904081
Hornykiewicz O. Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA). Mov Disord. 2010;25(1):S3-S8. PMID:20187247
Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord. 2012;27(1):8-30. PMID:21850488
Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain: II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 1999;122(8):1437-1448. PMID:10430830
Bjorklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007;30(5):194-202. PMID:17408759
Parent A, Hazrati LN. Functional anatomy of the basal ganglia: I. The cortico-striato-pallido-thalamo-cortical loop. Brain Res Rev. 1995;20(1):91-127. PMID:7711765
Category: Cell Types | Brain Region: Midbrain | Neurotransmitter: Dopamine